Tissue factor pathway inhibitor-2 may interact with nuclear protein RASSF1C

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 2, 2012, Pages 183-185

  Chen, Xudong ^a   Li, Zhenwu ^a   Zhang, Jin ^a   Mao, Zuohua ^a   Ma, Duan ^a   Wang, Huijun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PLACENTA PROTEIN 5; PRIMER DNA; RASSF1 PROTEIN, HUMAN; RECOMBINANT PROTEIN; TISSUE-FACTOR-PATHWAY INHIBITOR 2; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL LINE; CHEMISTRY; CONFOCAL MICROSCOPY; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; TWO HYBRID SYSTEM;

BASE SEQUENCE; CELL LINE; DNA PRIMERS; GLYCOPROTEINS; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEINS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84863070738     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmr123     Document Type: Article

References (13)

1. Chand HS, Foster DC and Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost 2005, 94: 1122-1130.
2. Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P and Schönbeck U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001, 107: 1117-1126.
3. Crawley JT, Goulding DA, Ferreira V, Severs NJ and Lupu F. Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2002, 22: 218-224.
4. Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S and Rao JS. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 2001, 7: 570-576.
5. Konduri SD, Tasiou A, Chandrasekar N and Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001, 18: 127-131.
6. Konduri SD, Tasiou A, Chandrasekar N, Nicolson GL and Rao JS. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 2000, 18: 303-308.
7. Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY and Tung EK, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007, 45: 1129-1138.
8. Ran Y, Pan J, Hu H, Zhou Z, Sun L, Peng L and Yu L, et al. A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma. Hum Gene Ther 2009, 20: 41-49.
9. Kempaiah P, Chand HS and Kisiel W. Human tissue factor pathway inhibitor-2 is internalized by cells and translocated to the nucleus by the importin system. Arch Biochem Biophys 2009, 482: 58-65.
10. Pfeifer GP and Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc) 2005, 70: 576-583.
11. Agathanggelou A, Cooper WN and Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005, 65: 3497-3508. Review.
12. Liu L, Vo A and McKeehan WL. Specificity of the methylationsuppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5. Cancer Res 2005, 65: 1830-1838.
13. Liu L, Tommasi S, Lee DH, Dammann R and Pfeifer GP. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003, 22: 8125-8136.